Prostate cancer (PCa) is a common cancer in men, requiring accurate diagnosis and monitoring of treatment efficacy for in time revealing and eliminating cancer relapse. Radical prostatectomy is the ...
Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...
New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.
Adding apalutamide to ADT in the adjuvant and neoadjuvant settings improves outcomes in prostate cancer patients undergoing ...
A pretreatment MRI in men undergoing radical prostatectomy can provide independent prognostic value for oncologic outcomes, a systematic review and meta-analysis indicated. MRI-detected extraprostatic ...
Wider resection of localized high-risk prostate cancer at surgery may come at the cost of sexual function and urinary incontinence. A phase 2 trial tested the merits of neoadjuvant therapy.
Among men with PSA persistence after radical prostatectomy, a higher preoperative PSA surprisingly was linked to lower mortality. Men with PSA persistence and preoperative PSA >20 ng/mL had 31% lower ...
PSMA PET has become central to prostate cancer imaging as advanced disease incidence rises and prostate-specific membrane ...
Impact of a rash management guide on incidence and severity of rash with apalutamide: Experience from the Apa-RP study in high-risk localized prostate cancer. This is an ASCO Meeting Abstract from the ...
Prostate cancer surgeons routinely use MRI to guide surgical planning, yet imaging findings are not used for risk stratification in standard prognostic models. A new meta-analysis suggests they should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results